RE: Low Volume today :P25 May 2020 11:44
There are multiple streams of news you can/may expect to see in the coming days and weeks.
First, we have been forewarned about imminent news that was due in late April:
"The collaboration agreement, originally scheduled to complete in late April 2020, is being extended by a short period due to the impact on GlobalCo's operations of the novel coronavirus, following which Hemogenyx will either license the antibody to GlobalCo or will in-license GlobalCo's improvements to it on favourable terms."
This is not covid related but may now have a covid element which boosts its impact. Expect a significant rise based on contents.
The "Super Mice": Basically we are in the dark as to who wants them but hemo have stated this:
"As with the original Advanced Hematopoietic Chimera, the Company believes that the ApbHC will be of considerable interest to other drug developers and interest shown to date is promising." There is a HUGGEEE market for these mice, question is, how many are we breeding, are we breeding enough to sell and what contracts profits are now forthcoming.
Orgenesis:
"Hemogenyx-Cell has been considering plans with a number of potential Belgian-based partners, including Orgenesis, Inc. - the provider of funding to Hemogenyx-Cell and also to Immugenyx in a separate agreement through convertible loans - regarding key building blocks for the path through development towards clinical trials of Hu-PHEC, including the establishment of a cell bank." Basically our name is all over Orgenesis literature and presentations. Whilst we have not released formal confirmation they certainly have used our name extensively. They have a 3 pronged approach to Covid and we seem to be involved there also.
These are just a few of the highlights there are lots of other potential news announcements that could appear in the weeks to come any of which could be significant. Whats worth remembering though is:
recently there was a share placing, investors, behind closed doors, were convinced to pump in 2.5m in a price that was only a small discount to the market price. That placing gets voted on 4th June, before AGM, at AGM or shortly after we are expecting significant news on any or all of the above topics.
Longer term we are looking at Phase 1 and Phase 2 Leukemia trials which if positive will change the playing field regarding hemo overnight.
Also to be expected: Potential TR1's. you MIGHT find one regarding the forced sale of the Bauer shares RE the outstanding HNW loans, and you may find surprise investors hitting the 3% mark. Likely we are in an insider blackout so unlikely to see any directors trading at this time.